| Detection of a SARS-CoV-2 variant of concern in South Africa H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, ... Nature 592 (7854), 438-443, 2021 | 1466 | 2021 |
| Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, ... medrxiv, 2020.12. 21.20248640, 2020 | 1198 | 2020 |
| Sixteen novel lineages of SARS-CoV-2 in South Africa H Tegally, E Wilkinson, RJ Lessells, J Giandhari, S Pillay, N Msomi, ... Nature medicine 27 (3), 440-446, 2021 | 362 | 2021 |
| HIV treatment adherence, drug resistance, virologic failure: evolving concepts JB Nachega, VC Marconi, GU Van Zyl, EM Gardner, W Preiser, SY Hong, ... Infectious disorders drug targets 11 (2), 167, 2011 | 305 | 2011 |
| Adult antiretroviral therapy guidelines 2017 G Meintjes, MA Moorhouse, S Carmona, N Davies, S Dlamini, ... Southern African journal of HIV medicine 18 (1), 1-24, 2017 | 236 | 2017 |
| Kosakovsky Pond SL, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. Detection of a SARS-CoV-2 variant of concern in South Africa H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, ... Nature 592 (7854), 438-443, 2021 | 215 | 2021 |
| A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa E Wilkinson, M Giovanetti, H Tegally, JE San, R Lessells, D Cuadros, ... Science 374 (6566), 423-431, 2021 | 188 | 2021 |
| Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings MC Hosseinipour, RK Gupta, G Van Zyl, JJ Eron, JB Nachega The Journal of infectious diseases 207 (suppl_2), S49-S56, 2013 | 169 | 2013 |
| Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, ... Nature 592 (7854), 438-443, 2021 | 147 | 2021 |
| Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting GU Van Zyl, TE Van Mens, H McIlleron, M Zeier, JB Nachega, E Decloedt, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (4), 333-339, 2011 | 132 | 2011 |
| HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ... PloS one 10 (12), e0145772, 2015 | 102 | 2015 |
| Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy ET Marinda, J Hargrove, W Preiser, H Slabbert, G Van Zyl, J Levin, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 53 (4), 496-499, 2010 | 101 | 2010 |
| The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance H Tegally, JE San, M Cotten, M Moir, B Tegomoh, G Mboowa, DP Martin, ... Science 378 (6615), eabq5358, 2022 | 91 | 2022 |
| HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens W Fischer, EE Giorgi, S Chakraborty, K Nguyen, T Bhattacharya, J Theiler, ... Cell host & microbe 29 (7), 1093-1110, 2021 | 84 | 2021 |
| No evidence of HIV replication in children on antiretroviral therapy GU Van Zyl, MG Katusiime, A Wiegand, WR McManus, MJ Bale, ... The Journal of clinical investigation 127 (10), 3827-3834, 2017 | 84 | 2017 |
| Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first-and second-line antiretroviral treatment regimens GU Van Zyl, TF Liu, M Claassen, S Engelbrecht, T De Oliveira, W Preiser, ... PloS one 8 (6), e67188, 2013 | 83 | 2013 |
| Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen R Fisher, GU van Zyl, SAA Travers, SL Kosakovsky Pond, S Engelbrech, ... Journal of virology 86 (11), 6231-6237, 2012 | 77* | 2012 |
| Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting GU Van Zyl, W Preiser, S Potschka, AT Lundershausen, R Haubrich, ... Clinical Infectious Diseases 52 (2), 264-270, 2011 | 77 | 2011 |
| Early Antiretroviral Therapy in South African Children Reduces HIV-1–Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells GU van Zyl, MA Bedison, AJ van Rensburg, B Laughton, MF Cotton, ... The Journal of infectious diseases 212 (1), 39-43, 2015 | 76 | 2015 |
| Future technologies for monitoring HIV drug resistance and cure UM Parikh, K McCormick, G van Zyl, JW Mellors Current Opinion in HIV and AIDS 12 (2), 182-189, 2017 | 75 | 2017 |
